Q3 2022 Cellectis SA Earnings Call
[music].
Okay.
[music].
Greetings and welcome to select a third quarter 2022 earnings conference call. At this time all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance. During the conference. Please press star zero on your telephone keypad as a reminder.
Sure.
This conference is being recorded it is now my pleasure to introduce your host Arthur's trial Chief business Officer. Thank you Sir you may begin.
And welcome everyone to selected third quarter 2022, corporate update and financial results Conference call.
Joining me on this call today with prepared remarks are doctor homepage leak out our Chief Executive Officer, Dr. Wang Our Chief Financial Officer, and Dr. Marc <unk>, our Chief Medical Officer.
Yesterday evening selected filed its interim reports and issued a press release reporting its financial results for the third quarter and nine months period ended September 30th 2022.
The report and press release are available on our website at selected Dot com.
As a reminder, we will make statements regarding selected financial outlook. In addition to its manufacturing regulatory and product development status and plans and product development of its license partners.
These forward statements, which are based on management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our license partners.
Object to risks and uncertainties that may cause actual results to differ from those forecasted.
A description of these risks can be found in our most recent form 20-F filed with the SEC and our financial reports, including the management report for the year ending on December 31, 2021, and subsequent filings select this makes with the Securities Exchange Commission from time to time.
I would now like to turn the call over to Andre.
Thank you Arthur.
Good morning, and thank you everyone for joining us today.
2022 has been a productive year, thus far for select us.
We have made progress on all fronts that we're thrilled to share with you today yesterday, we've announced that are you cut 123 abstract was accepted for an oral presentation at the American Society of Hematology annual meeting, we're excited to share preliminary data from them.
Emily Zero one trial.
Which is a dose escalation and dose expansion study evaluating the safety expansion persistence and clinical activity a few car T 123 in patients with relapsed or refractory acute leukemia.
Acute millage leukemia is a huge unmet medical need with a lack of cell therapy options and these encouraging clinical data are great step forward for patients. We're also proud that the Amsterdam University Medical Center will present preclinical data at ash on our product.
Candidate you car T T S, one, which reinforces the validation of <unk> as a relevant target for relapsed and refractory multiple myeloma patient.
Select this continues to make progress enrolling patients and it's for sponsored Allogeneic car T trials.
We will soon initiate dosing patients with our product candidate you car T 22, and your car T. Twenty's by 'twenty two that have been fully manufactured in house.
This will be a significant milestone for selected highlighting how our investment in building our GMP manufacturing facilities has now provided the company with independents and control over our gene and cell therapy processes.
We believe that.
Bringing manufacturing fully in house could contribute to eliminating some of the barriers.
Netted are facing are facing.
So as to provide consistency and safety in our production and shorter lead times are met and adaptability.
Fortunately.
Having our manufacturing in house means that we can rapidly optimize.
Promising therapeutic candidates as we monitor clinical responses, leading to the best possible product at registration filing.
This quarter our partnership.
Continued to be a highlight for selected several of our partners disclosed exciting milestone.
Allergy and now.
That it was starting the first allogeneic car T potentially pivotal phase II trial for patients with large b cell lymphoma.
We share allo jeans excitement for this accomplishment as it paved the road for both Allo 501, a and our broader pipeline of allergenic candidate product too.
So greatly increased patient access to cell therapy.
Our licensed partner I events.
Announced that the first patient was dosed and completed the safety observation period.
I O V. G M. One two O one clinical trial for <unk> for genetically modified Palin edited tumor infiltrating lymphocyte or til therapy for.
<unk> for the treatment of previously treated metastatic non small cell lung cancer and advanced my melanoma.
Finally, our partners I told you announced that it will present, new preclinical data on Palin gene edited induced pluripotent stem cell derived natural killer cells at the society of immunotherapy of.
Cancer's annual meeting that will take place in November .
These achievements showcase once more that selected along with this gene editing technologies such as tailing is the partner of choice for cell and gene therapy applications across a wide range of cell types and that we're continuing to deliver on our promises.
Constant innovation in order to advance the efforts of both our and our partners' clinical trials with that I'd like to turn the call over to Mark for team.
Newly appointed Chief Medical Officer.
Most of you know mark.
He has been serving as a core member of the senior clinical team over the past two years previously.
As a senior Vice President of clinical Science, Mark will give an overview of our sponsored clinical trials and preclinical product pipeline Mark. Please go ahead.
Thank you Andre and good morning, everyone as Ondrej mentioned.
2022 has been a busy and productive year for something like this with our proprietary clinical and preclinical programs, making progress and we're specifically excited to share additional preliminary clinical data from our homily O. One trial in an oral presentation at the Ash annual meeting.
Meeting next month.
The abstract for Emily Oh, one includes preliminary clinical data from the phase one open label dose escalation study in patients with relapsed or refractory acute myeloid leukemia, showing that adding Alan he's a man to the Fludarabine cyclophosphamide limpid depletion regimen or apps.
The regimen was associated with improvements depletion and significantly higher new car at 123 cell expansion, which correlated with improved clinical activity.
These data are encouraging and supports the continued enrollment into the study.
The abstract for you Carl C. S. One presented by the Amsterdam University Medical Center includes preclinical data demonstrating anti tumor activity in vitro and in vivo and supported the initiation of the first in human study of U C. S. One so like this is.
As Melanie Oh, one clinical study.
So that just continues to progress in its phase one clinical trials evaluating its for proprietary allogeneic car T cell therapies in hematologic malignancies.
Bally O one evaluating <unk> 22 in patients with relapsed or refractory b cell acute lymphoblastic leukemia.
Emily Oh, one evaluating <unk> 23 in patients with relapsed or refractory acute myeloid leukemia, Melanie O one evaluating new car T. S. One in patients with relapsed or refractory multiple myeloma.
Last quarter, we were pleased to announce the F. D. A I N D clearance for our product candidate you card 20 by 20 to select it as first Allergan, a dual car T cell product candidate being developed for patients with relapsed or refractory non hodgkin lymphoma.
Your cards plenty by 'twenty two is so like this first product candidate fully designed developed and manufactured in house showcasing the company transformation into a true end to end cell and gene therapy company.
In addition to the exciting clinical updates we have several additional preclinical updates.
In October so I suppose presented data on two tailwind based gene therapy preclinical programs for patients with sickle cell disease, and Mucopolysaccharide doses type one at the European Society for gene and cell therapies annual Congress.
The preclinical data further demonstrating our ability to leverage tailing gene editing technology to potentially address genetic diseases, namely sickle cell disease and lysosomal storage diseases.
By correcting a mutation or inserting a corrected gene at the hematopoietic stem cell level. So like this aims to provide a lifelong supply of healthy cells from a single intervention.
Lastly, select us announced that two poster showcasing preclinical data on tailing edited smart car T cells for solid tumors will be presented at the society for immunotherapy of cancers annual meeting on November 10.
The first poster will be on tailing edited smart car T cells targeting muck, one expressing solid tumors.
One is a tumor associated antigen that is over expressed in triple negative breast cancer and other solid tumor malignancies.
The second poster will be on innovative T cell engineering strategies designed to increase the activity of car T cells for solid tumors, while mitigating toxicity risks.
With that I would like to hand, the call over to being one. So this is finance chief financial officer for an overview of our financials for the third quarter of 2020.
Ben Please go ahead.
Thank you Mark.
I will provide a brief overview of our financials for the third quarter of 2022.
I'd like to highlight that our financials cash cash equivalents current financial asset.
Restricted cash position was select us excluding calix.
The September 32022 was $95 million compared to $177 million as of December 31, 2021.
This difference mainly reflect $81 million of net cash flow used in operating investing and lease financing activities and $10 million of negative foreign exchange impact, partially offset by 6 million of cash received related to research tax credit pre financing and 3 million cash.
We see for milestones and license fees.
Based on our current operating plans and financial projections. This cash position is expected to be sufficient to fund so I'd like to stand alone operations into early 2024.
The consolidated cash cash equivalents current financial assets and restricted cash position of select us, including Catholics was $103 million as of September 30th 2022, compared to 191 million 191 million as of December 31st 2021.
The net cash flow used in operating capital expenditure and leases were 81 million S. L. Like this 17 million our colleagues in the first nine months of 2022, partially offset by a 10 million capital raise our colleagues.
6 million of cash receipt related to research tax credit pre financing I felt like this and.
And 3 million cash receipt from milestones on licenses.
The net attributable loss to shareholders of select this excluding colleagues with 73 million in the first nine months of 2022 compared to a loss of $75 million in the first nine months of 2021.
This 2 million decrease in net loss between 2020, two and 'twenty 'twenty. One was primarily driven by a decrease of R&D expense of $12 million an increase in net financial gain those 7 million, partially offset by a decrease in revenues and other income of $18 million.
The consolidated net loss attributable to shareholders of select us, including colleagues with 79 million.
Or $1.74 per share in the first nine months of 2022 compared to a loss of $89 million or $2 per share in 2021.
The consolidated adjusted net loss attributable to shareholders of select us excluding calix, excluding noncash stock based compensation expenses was $67 million or $1.40 per share in the first nine months of 2022 compared to a loss of $66 million.
Well, one dollar and 49 cents per share in 2020 one.
We are laser focused on spending our cash on developing our deep pipeline of wholly owned product candidates in the clinic and operating our state of the art manufacturing facilities in Paris and in Raleigh.
On the other hand, our focus on maintaining an efficient corporate infrastructure should they should enable more limited growth in G&A spend going forward.
Thank you Ben.
We're excited about all clinical and preclinical data select this has generated and will continue to generate we're also excited by the progress with our partners.
Electus continues to make progress with our pipeline highlighting our forest ongoing four ongoing clinical trials and hematology malignancies. This quarter as we make steps closer to becoming a true end to end cell and gene therapy company.
These update clear.
Clearly show, our potential and a belief T to advance the field of allogeneic car T cell therapy.
With that I'd like to open the call for question and answers. Thank you.
Thank you we will now be conducting a question and answer session. If he would like to ask a question. Please press star one on your telephone keypad, a confirmation tone will indicate your line is in the question queue.
You May press Star two if you would like to remove your question from the queue.
Perfect. Thank speaker equipment, it may be necessary to pick up your handset before pressing the star keys, one moment, please while we poll for questions.
Our first question comes from Gena Wang with Barclays. Please proceed with your question.
Thank you for taking my questions and congrats on all the progress and we look forward to the data.
In the next few weeks, so we did see the apps.
Abstract from Ash abstract yesterday or from the U car 123 program. So maybe just you know thoughts do you have what is your goal regarding C activity, we like or do you see you know.
We shall wrung out of the E S. P. A.
I'm sure the CRE and very doable and if so what are what would be the the actual coal that you wanted to achieve that you think it will be competitive and then giving this clear benefit with Alan to snap a how would you apply this broadly applied as to the other program.
Hi, Gena. Thank you so much for the question do are both great questions I will hand, it over to Mark.
Hi, Gena. Thanks for thank you for the question so.
I think I'll answer the second one first so in regards to the she's a mab.
You know I think the data.
That we're presenting about the effect of Alemtuzumab in terms of prolonging, the lymphoid depletion and allowing.
For your current expansion and clinical activity.
That we're going to present for 123 echoes what we've seen for <unk> 22, and was presented at Ash last year and I think overall.
Points out to the importance of Alemtuzumab in our new card programs for the.
The products that have the CD 52 gene knocked out using our tailored technology. So I think as we move forward. It's it's definitely definitely really important to proceed with the on Tuesday may have been the regimen.
As far as the the data for <unk> hundred 23, we're incredibly excited by what we've seen.
I think as you know we've discussed before and as everyone knows these are really heavily heavily pretreated patients who have essentially failed everything.
And as you can see from the from the abstract data over 50% of the patients have also failed allogeneic transplant and for people for patients like this there are really no other treatment options and their life expectancy is very very short. So the fact that we were able to achieve a long term memory.
The negative CR, that's been durable in a patient is incredibly incredibly exciting and the dose escalation part of this study.
The other thing to point out is the other responder and the FCA regimen, albeit stable disease was a patient that had over 90% blast reduction on day 28. So again very encouraging response as we proceed forward with the dose escalation part of this study.
Okay.
Thank you very much.
Our next question comes from Jack Allen with Baird. Please proceed with your question.
Alright. Thank you so much for taking my questions and congratulations on the progress over the course of the quarter.
I wanted to ask you about some of the milestone payments that you were expecting to receive from <unk>.
And I guess essentially from Ey event than I felt allergy and for initiating the pivotal study.
Given that those those are I guess milestones had been hit at this point I was hoping you could maybe provide some more color as to what size of those milestone payments.
Additionally, any comments you can provide as it relates to the Saturday a relationship and a I guess your path forward there as well it would be great.
Thank you Jack Great question, maybe being on the milestone and then probably Andre on the assembly of relationships.
Okay.
Yeah. So for the purpose of this call we're going to focus on Q3, which ended on September 30th So in terms of any progress that happens in sandwell withholds common for now.
And Florida, serving allergy and situation actually we think that we've seen that there is definitely good possibilities that that should be resolved and as the situation is progressing and also we're expecting some.
Milestones to be reached on the allergy inside into develop enough Allo 501, a stated endured near Q3, our press release and there are coal we are very optimistic that the great product like this should find a path forward.
Great. Thanks, so much.
Our next question comes from EXL knock on effects with Citigroup. Please proceed with your question.
Yeah, Hi, I just had a quick question regarding your manufacturing is the long term planning also to have the <unk> card.
Yes.
Manufactured in here.
<unk>.
Okay.
How do you go yeah, Great question I think on this definitely the plan is to leverage that are fully internal manufacturing capabilities are selected we're extremely proud to now have the entire car T value chain in house, ranging from starting material classmates mrna viral vectors all the way to the allogeneic car T.
So the plan is definitely are in the long run to transition all of our programs to these internal platform absolutely.
Got it and then you announced the deal with targeted.
'twenty two.
Yeah.
I'm just wondering.
Should we be expecting more of the dual antigen type products coming forward or CD 2022.
No more of a like a one off for the Atlanta Jim.
Okay, but also great question, Andrea do you want to take this one.
Sure of course, thank you eat golfer to question. The dual targeting is extremely interesting for numerous reasons like the first allogeneic car T that will be tested for dual targeting.
The big advantage of having two cars expressed in the same T cell.
Gives you more chances to be able to grasp tumor.
The tumor associated antigen on the surface of the cancer cell in form of <unk>.
<unk> seen out to better killing and that's the hypothesis behind all of this development.
Development that we're doing so the killing that we see so far in preclinical.
Settings is very encouraging and the data that we have is oh.
It was very solid so the cell can kill CD 20, and Unexpressive CD 22, or <unk> 22 in the next break, saying CD 20 cells and of course, both expressing.
However in patients you see wobbling on the both targets. It means the expression or density on these like CD 20, and CD 22 can there right. So single targeting car T.
Can some times have some escapes due to the lack of good formation of D. C. Naps and if there is like the two targets that are expressed on the cell. So the synapses better formed into killing is better done. That's the hypothesis. So we're going to test. This at first but there are definitely plans to move forward in this strategy.
And so we will analyze the data from the Napoli trial that is about to start.
Okay.
Our next question comes from Celgene restart with Goldman Sachs. Please proceed with your question.
Hi, good morning, and thanks for the question. This is Mason on for solving could you. Please remind us of the status of the EU card 'twenty, one 'twenty two program and whether it's still on track for the second half of 'twenty two.
And could you also give us an overview of which key catalysts, we should look to by mid 'twenty three.
Thanks.
Hi, Thanks for the question I'll hand, it over to Mark.
So thank you so for the 20 by 'twenty two absolutely. We're on track as you know we received the safe to proceed from the F. D. A on August 1st and so we are in process of opening sites and and plan to begin enrollment in Q4 of this year.
Andrea do you want to take the broader question on the key catalysts.
Sure actually thank you very much for the question and its appreciated we believe that's like this was four clinical trials that are ongoing.
Was like CD 22 targeting C. D 123 targeting C D a C.
She has swung targeting and TD twenty-two by CD 20 is a very will.
Will will provide numerous data points.
The first one is that we have already an oral presentation at ash as Mark has said and that's where we give an update on on the acute <unk> leukemia trials for your car T 123.
But two we're also communicating simulating data in the other trials and we will.
Have to at least start as Mark just said for.
The dual targeting car T car T 20 by 'twenty two enrollment this year, so a little before the end of the year.
And that would make a 'twenty 'twenty three very much rich and event starting now actually from like the end of this year and through 2023 of course. This is a about all our car T. But we expect also some meaningful data points from our partners our events in our sights.
<unk> and Allo Gene survey of course, thank you.
Yeah.
Thank you.
Our next question comes from David Dye with S. M. D. C. Please proceed with your question.
Okay, great. Thanks for taking my questions and also long congrats on the progress first of all it's just on the <unk> sell tea party 20th by playing too.
Wondering if you can share some high level thoughts on clinical trial design so far.
Thank you David and Mark I think this is for you.
So so thanks, so so as we begin I can't really share a lot right now in terms of what's happening, but you know as we discussed in our prior question from Gena, obviously, they use about teens, a mab will be important and they'll info depletion regimen for this study.
Got it that's helpful and just another question on the the response from the car T. At 123 patients. So it seems so far in both the F. C N FCA arms are especially interested in the.
Doable and Martin you made a patient who has to have a responsible about eight months and so far. So I'm wondering if you can share some additional color on that the characteristics of the patient.
This patient has high assumption.
Uh huh.
Risk or any any kind of thoughts would be helpful. Here.
Yeah. Thanks for thanks for that so what I can share with you right. Now is just what's in the abstract because the rest is obviously embargoed until the presentation, but this patient in particular was an older patient as outlined in the abstract that it fail five prior lines of therapy include.
<unk> and allogeneic stem cell transplant Ah you know, which as you know in this case is.
We discussed before is really in this patient population sort of the worst of the worst so a great response.
Okay.
Alright. Thank you so much for taking my questions.
Our next question is from <unk> Singh with Oppenheimer and company. Please proceed with your question.
Great. Thank you and thanks for the updates I just got a couple of questions. One is.
Can you just talk a little bit about you want to treat and she has won what dose levels are you. There you might have mentioned before I missed sorry, if I missed it I apologize and then what line patients are you seeing there I know AML multiple myeloma.
Have multiple multiple lines of therapy. If you can just kind of remind us what line of patients you're seeing in your clinical trials there for one to three and since one specifically and then secondly.
There seem to be other companies interested in this post CD 19 treatment car T treatment kind of area.
Aside from the clinical design can you just talk about you know how.
How big this market is from a patient perspective.
How large is that getting now with all the C 19 therapies out thanks for the questions.
Hi, I heard that and I. Thank you for both question I think the first one would be for Mark and then probably being can give us some color on the market sizing question.
Okay. Thanks, our towers for the question.
And in terms of the lines of therapy for for both of these studies.
Obviously these are very advanced and highly refractory patients.
You know for the 123 abstract what what's out there as these people have had an average of four prior lines of therapy up to nine prior lines of therapy for the 123 studies. So for 123, they failed they failed everything including allo transplant in over 50.
A sign of the of the patients. So it's really last treatment option for the patients with 123 for.
For C. S. One what what we can disclose is that as you know the trial it reopened after.
After it had been on a hold from.
From the F D a and were continuing in the dose escalation.
Part of that study.
And again. These are again are the same way in terms of patient eligibility criteria includes failing or be CMA directed therapy, both antibody as well as card prior car T therapy, so highly refractory patients for for both studies as.
As far as the dose levels for $1 23 goes it's in the abstract so we're at we're at dose level, two and two I for FCA will be reported.
And.
And being you want to take the question on the market side.
Thank you for the question hard size I think that's a very critical question at this point I think you know I think a lot of the indication. We go after the primary cell therapy solutions are still a tall Lewis I think one thing that we need to think about is that there's only about 150 transplant centers in the entire United States. This is reported by C. N N.
And in August of this year.
If you were to think of that number and those are the institutions have the capability to do a target therapy. It actually caps. The total capacity for autologous treatment in the entire United States. So at 150 centers and if you were to even put an optimistic estimate of six patients a month that is only about a 10000.
<unk> for the entire United States every year for all autologous therapy, that's bcm, a CD 19, combined so I think if we were to focus on that fact, then we realized that the current some of the current limitation with Targa is really not just capped by manufacturing as even we thought at the beginning of the year. It was really.
Cat by the hospital infrastructure in the United States and this is not something that big pharma can just throw a few hundred million dollars in a new vector plant to solve so I think once you know both ourselves as well as our partners the survey and algae launch commercially viable allogeneic cell therapy, we will cigna.
Killing expand the market so that means in my home State of California. For example people don't have to go to UCSF with city of hope where Stanford they can potentially go to Kaiser for for a lot of these similar treatment. So the potential market size with a product that both ourselves and our partner will plan to launch will significantly expand our cell therapy.
Well beyond what is available today.
Great. Thank you bank, Thanks, Mark I really appreciate the questions.
Our next question is from Yanan, Zhu with Wells Fargo. Please proceed with your question.
Hi, Thanks for taking my questions.
About the C. Our patient in the Ash abstract Oh, it was a quite durable eight months as of the cutoff date of July 2022, just wondering if you can comment if that patient is still in response correctly and also does this suggest a depth.
The response for this indication.
Could be important and persistence may not be as important.
In this indication and also if you can talk about how are.
Are you thinking about the dose going forward for the F C arm off.
Obviously, you have a when you have a one P. L. T out of eight patients at this arm and they'll listen I want to but for the F. C. Arm you do have I think a high higher frequency of Ts.
The higher level.
But two I N D O three so how should.
Should we think about your ability to increase that those are in the S. C. A arm. Thanks.
Thank you, Matt and thank you for this a good set of questions on the 123, so mark over to you.
Hey, Thanks for the thanks for the questions let.
Let me see if I get them all right going through but in terms of your first question, yes, and in terms of the data cut off their patients' response was over eight months.
Which was reported in the abstract Unfortunately as you know the the presentations embargoed until until the time of presentation. So I really can't go into more detail than that right now.
In terms of your second question in terms of depth of response, you know I think.
One of the things we know about this being an allogeneic car T product that we're not necessarily going to get long term persistence and I think the fact that we see advocacy and we see a <unk> negative CR.
At an early time point as you pointed out is is important.
Again, I would point out that patients such as this or are usually lifespan is measured in weeks.
And so the fact that we were able to you know the patient was able to achieve a response.
I like this with the with the car T cell is fantastic.
And then to your last question, which is a great one and and will be addressed in the presentation, but unfortunately I can't go into any more details right now.
Great. Thanks for all the color I appreciate it appreciate it thanks.
Our next question comes from Raju Prasad with William Blair. Please proceed with your question.
Hi, Thank you for taking our question. This is Brett on for Raj.
So regarding <unk> three again I was wondering if you've seen any correlation of patient baseline characteristics. Even if it is like relatively small that correlate with better responses to the therapy.
Yeah.
Hi, Thank you for the question Mark and your thoughts on this high broke yes. Thanks for the question I think that you know one thing that's clear from you know the table that is included in the Ash abstract is that you know there's there's really these are really the patients.
That it failed everything and as you can tell also that they have extremely high risk disease with multiple cytogenetic and high risk molecular mutate.
Mutations given that you know over 80% of them were adverse risk by the E. O N criteria. So I think there's you know there'll be more discussed during the presentation, but I think the.
These high risk patients have had you know that we've seen multiple you know several responses in but you know we're talking about the <unk> negative CR, but the other patients are in the FC cohort that was somebody who had a 90% blast reduction by day 28.
And achieving stable disease will will also also be discussed so hum.
Anyway, you kept.
Thanks.
Thank you so much.
Our next question comes from Luisa Mercado with Kempen. Please proceed with your question.
Hi, Thank you for the update and for <unk>.
Allowing me to take my questions I wanted to ask a few things so first on the.
On the global bond issue with Allergan and the Servier agreement, what's are the exact hurdles in disagreement.
And what are the risks for the 501 programs in terms of development.
So thanks Louise for the question I. This is an ongoing matter. So I don't think we will comment further as this is being resolved as Andres discussed.
But we don't anticipate any issues on the development itself up to fiber one a program and we're particularly excited that our allergy and announced a few weeks ago that this program was entering.
Phase two pivotal trials. So I think this is a there's both what this bodes well for the future of the program and our allogeneic car T franchise as a whole.
And then on your manufacturer manufacturing facility I wanted to.
If you could give me a bit more details on whether it's up and running at which point then oh, so whether this.
It'll be used for products outside of Philly.
Yeah, Great question, So, it's definitely up and running and it has already manufactured and released product. So it's a manufactured you got 20 by 'twenty two for which we got the IND approved.
And the so called second doesn't P. Two version a few Cal 'twenty two.
So we have been swapping you got 22 manufactured previously from our CMO into project manufacturer that rally. So you got 22 are new Cal 'twenty by 'twenty two have been manufactured in our facilities, which are definitely up and running and that's mentioned to a previous question. The plan is to cover our entire pipeline in the future.
Regarding partnerships definitely there is room for spare capacity for potential partnerships, we do not aim to become a C. D. M O, but we could definitely leverage the manufacturing facility in broader partnership deals around the car T around some of the starting materials. So this is definitely a fantastic asset for selected.
Okay. Thank you.
Yeah.
There are no further questions at this time I would now like to turn the floor back over to Arthur strokes for closing comments.
Thank you very much everyone. We're very excited about the progress moving forward.
As long as I mentioned, there will be a number of exciting catalysts on our clinical trials moving forward. We're also particularly excited to have the full end to end platform for allogeneic cell therapy activities, ranging from discovery manufacturing product development and all the way through clinical development.
The future is a is very exciting and we are looking forward to the next update including the ones on you've got one to two and you can see that's why I'm at Ash in December . Thank you very much everyone for connecting today.
Yeah.
This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.
Yeah, good stuff guys.
Good.
[music].
Yeah.
Yeah.
[music].
Okay.
Okay.
Okay.
[music].
Yes.
[music].
Okay.
[music].
Yeah.
[music].
Uh huh.
Yeah.
Yeah.
[music].
Okay.
Mhm.
[music].
Yes.
[music].
Yes.
[music].
Mhm.
[music].
Okay.
[music].
Okay.
[music].
Uh huh.
[music].
Yes.
[music].
Uh huh.
Okay.
[music].
Okay.
Yeah.
[music].
Yes.
[music].
Uh huh.
Yeah.
[music].
[music].
Okay.
Okay.
Okay.
[music].
Okay.
Okay.
[music].